WHATNEXT partner website Patient Worthy recently published an article about a real-world research study which documented the effect of a combination treatment for younger patients living with acute myeloid leukemia.
Writer Rose Duesterwald shares:
“Recent advances in AML therapy are attributed to the combination of VEN, a B-cell lymphoma 2 (Bcl-2) inhibitor, plus hypomethylating agents (HMAs).
VEN is a BCL-2 inhibitor that improves outcomes for patients with relapsed and refractory AML. The agent blocks an anti-apoptotic BCL2 gene, responsible for protecting cells from inadequate blood supply-induced apoptosis. If apoptosis is blocked, it can lead to prolific cell division and new tumor growth.”
Check out the full story here.
Editor’s Note: Get Involved
Cancer doesn’t discriminate. WHATNEXT and its partners are interested in amplifying the voices of those from all identities and backgrounds. If you have a cancer journey to share, reach out here to learn more about how your voice can help spread awareness and inspire individuals from all walks of life.
acute myeloid leukemia AML leukemia research treatment
Last modified: July 29, 2024
